Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in nonhuman primates

被引:123
作者
Monath, TP
Soike, K
Levenbook, I
Zhang, ZX
Arroyo, J
Delagrave, S
Myers, G
Barrett, ADT
Shope, RE
Ratterree, M
Chambers, TJ
Guirakhoo, F
机构
[1] OraVax Inc, Cambridge, MA 02139 USA
[2] Tulane Reg Primate Ctr, Covington, LA 70433 USA
[3] Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA
[4] St Louis Univ, Ctr Hlth Sci, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA
关键词
D O I
10.1016/S0264-410X(98)00487-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Yellow fever 17D virus, a safe and effective live, attenuated vaccine, was used as a vector for genes encoding the protective antigenic determinants of a heterologous member of the genus Flavivirus, Japanese encephalitis (JE) virus, the leading cause of acute viral central nervous system infection and death throughout Asia. The viral envelope (prM and E) genes of a full-length cDNA clone of YF 17D virus were replaced with the corresponding genes of JE SA14-14-2, a strain licensed as a live, attenuated vaccine in China. Full-length RNA transcripts of the YF/JE chimaera were used to transfect Vero cells. The progeny virus (named 'ChimeriVax(TM)JE'), was used to define safety after intracerebral (IC) inoculation of rhesus monkeys. Monkeys (N = 3) inoculated with a high dose (6.6 log(10) pfu) developed a brief viremia, showed no signs of illness, developed high titers of anti-JE neutralizing antibody, and had minimal brain and spinal cord lesion scores according to criteria specified in the WHO monkey neurovirulence test. A control group of 3 monkeys that received a lower dose (4.2 log(10) pfu) of commercial YF 17D vaccine had slightly higher lesion scores. To develop a lethal monkey model of JE for vaccine protection tests, we inoculated groups of monkeys IC or intranasally (IN) with a JE virus strain found to be highly neurovirulent and neuroinvasive for mice. Monkeys inoculated IC, but not IN, developed severe encephalitis after an incubation period of 8-13 days. The ChimeriVax(TM)-JE virus was passed in a cell line acceptable for human use (diploid fetal rhesus lung) and 4.3 or 5.3 log(10) pfu were inoculated into groups of 3 monkeys by the subcutaneous route. All 6 animals developed brief viremias (peak titer < 2.0 log(10) pfu/ml) and subsequently had anti-JE but no yellow fever neutralizing antibodies, On day 64, the monkeys were challenged IC with 5.5 log(10) pfu of virulent JE virus. The immunized animals had no detectable viremia post-challenge, whereas 4 unimmunized controls became viremic. Only 1 of 6 (17%) vaccinated monkeys but 4 of 4 (100%) unvaccinated controls developed encephalitis. Histopathological examination 30 days after challenge confirmed that the protected, immunized animals had no or minimal evidence of encephalitis, These data demonstrated the ability of the ChimeriVax(TM)-JE: to induce a rapid humoral immune response and to protect against a very severe, direct intracerebral virus challenge, Target areas of neuronal damage and inflammation in monkeys infected IC with wild-type JE, the chimaeric virus and YF 17D were similar, indicating that the histopathological scoring system used for the WHO yellow fever monkey neurovirulence test will be applicable to control testing of chimaeric seed viruses and vaccines. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1869 / 1882
页数:14
相关论文
共 44 条
[31]   HETEROGENEITY IN ENVELOPE PROTEIN-SEQUENCE AND N-LINKED GLYCOSYLATION AMONG YELLOW-FEVER VIRUS-VACCINE STRAINS [J].
POST, PR ;
SANTOS, CND ;
CARVALHO, R ;
CRUZ, ACR ;
RICE, CM ;
GALLER, R .
VIROLOGY, 1992, 188 (01) :160-167
[32]  
RICE C M, 1989, New Biologist, V1, P285
[33]   NUCLEOTIDE-SEQUENCE OF YELLOW-FEVER VIRUS - IMPLICATIONS FOR FLAVIVIRUS GENE-EXPRESSION AND EVOLUTION [J].
RICE, CM ;
LENCHES, EM ;
EDDY, SR ;
SHIN, SJ ;
SHEETS, RL ;
STRAUSS, JH .
SCIENCE, 1985, 229 (4715) :726-733
[34]   Replication of yellow fever virus in the mouse central nervous system: Comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain [J].
Schlesinger, JJ ;
Chapman, S ;
Nestorowicz, A ;
Rice, CM ;
Ginocchio, TE ;
Chambers, TJ .
JOURNAL OF GENERAL VIROLOGY, 1996, 77 :1277-1285
[35]   PROTECTION AGAINST YELLOW-FEVER IN MONKEYS BY IMMUNIZATION WITH YELLOW-FEVER VIRUS NONSTRUCTURAL PROTEIN NS1 [J].
SCHLESINGER, JJ ;
BRANDRISS, MW ;
CROPP, CB ;
MONATH, TP .
JOURNAL OF VIROLOGY, 1986, 60 (03) :1153-1155
[36]   CHARACTERIZATION OF A HIGHLY ATTENUATED JAPANESE ENCEPHALITIS-VIRUS GENERATED FROM MOLECULARLY CLONED CDNA [J].
SUMIYOSHI, H ;
TIGNOR, GH ;
SHOPE, RE .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (05) :1144-1151
[37]   The use of yellow fever virus modified by in vitro cultivation for human immunization [J].
Theiler, M ;
Smith, HH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1937, 65 (06) :787-800
[38]  
THEILER M, 1951, YELLOW FEVER, P46
[39]  
TIGGERT WD, 1960, EXPT YELLOW FEVER, V22, P323
[40]   Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine - A comparison of 1- and 3-month immunization schedules [J].
Tsai, TF ;
Yu, YX ;
Li, JL ;
Putvatana, R ;
Zhang, R ;
Wang, SQ ;
Halstead, SB .
JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (01) :221-223